Abstract
Metabolic syndrome, a “cluster” of metabolic disorders including hypertension, increases the cardiovascular risk, and insulin resistance plays a key role in its pathogenesis. In this syndrome antihypertensive treatment with betablockers is underused because of their adverse metabolic effects. The aim was to review the evidences supporting the reasons for under-using beta-blockers in hypertensive patients with metabolic syndrome. A review of Literature has been carried out via PubMed from 1998 to 2008: most of beta-blockers have adverse effects on insulin sensitivity, carbohydrate and lipid metabolism, and are not recommended in metabolic syndrome. However, some recent large studies have shown a better metabolic profile with newer third generation vasodilating beta-blockers, such as Carvedilol and Nebivolol. Vasodilating action of Carvedilol and Nebivolol, due respectively to alpha1-blocking effect and release of nitric oxide, explains the lack of adverse metabolic effects of these beta-blockers that could also be used in hypertensive patients with metabolic syndrome.
Keywords: Antihypertensive, Beta-blockers, Metabolic syndrome
Current Diabetes Reviews
Title: Antihypertensive Treatment with Beta-Blockers in the Metabolic Syndrome: A Review
Volume: 6 Issue: 4
Author(s): Angelo M. Carella, Giuseppe Antonucci, Matteo Conte, Michele Di Pumpo, Armando Giancola and Elisabetta Antonucci
Affiliation:
Keywords: Antihypertensive, Beta-blockers, Metabolic syndrome
Abstract: Metabolic syndrome, a “cluster” of metabolic disorders including hypertension, increases the cardiovascular risk, and insulin resistance plays a key role in its pathogenesis. In this syndrome antihypertensive treatment with betablockers is underused because of their adverse metabolic effects. The aim was to review the evidences supporting the reasons for under-using beta-blockers in hypertensive patients with metabolic syndrome. A review of Literature has been carried out via PubMed from 1998 to 2008: most of beta-blockers have adverse effects on insulin sensitivity, carbohydrate and lipid metabolism, and are not recommended in metabolic syndrome. However, some recent large studies have shown a better metabolic profile with newer third generation vasodilating beta-blockers, such as Carvedilol and Nebivolol. Vasodilating action of Carvedilol and Nebivolol, due respectively to alpha1-blocking effect and release of nitric oxide, explains the lack of adverse metabolic effects of these beta-blockers that could also be used in hypertensive patients with metabolic syndrome.
Export Options
About this article
Cite this article as:
M. Carella Angelo, Antonucci Giuseppe, Conte Matteo, Di Pumpo Michele, Giancola Armando and Antonucci Elisabetta, Antihypertensive Treatment with Beta-Blockers in the Metabolic Syndrome: A Review, Current Diabetes Reviews 2010; 6 (4) . https://dx.doi.org/10.2174/157339910791658844
DOI https://dx.doi.org/10.2174/157339910791658844 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes
Current Diabetes Reviews Use of microRNAs as Anti-Atherosclerosis
Mini-Reviews in Medicinal Chemistry Pathogenesis, Clinical Manifestation, Diagnosis, Pathological Findings, Treatment Options, Preventive Measures, and Risk Factors of COVID-19
Coronaviruses Adonis sp., Convallaria sp., Strophanthus sp., Thevetia sp., and Leonurus sp. - Cardiotonic Plants with Known Traditional Use and a Few Preclinical and Clinical Studies
Current Pharmaceutical Design Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus?
Current Vascular Pharmacology The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine
Current Pharmaceutical Design Synthesis and In Vivo Acute Antihyperglycemic Evaluation of Novel Isosteviol Derivatives
Letters in Drug Design & Discovery Effect of Antihypertensive Drugs on Cognition and Behavioral Symptoms of Patients with Alzheimer’s Disease: A Meta-analysis
Current Pharmaceutical Biotechnology Modulators of Networks: Molecular Targets of Arterial Calcification Identified in Man and Mice
Current Pharmaceutical Design Benefits of Exercise Training in Secondary Prevention of Coronary and Peripheral Arterial Disease
Vascular Disease Prevention (Discontinued) Interaction of Cyclosporine A and the Renin-Angiotensin System New Perspectives
Current Drug Metabolism Obesity-Induced Cerebral Hypoperfusion Derived from Endothelial Dysfunction: One of the Risk Factors for Alzheimer's Disease
Current Alzheimer Research Electrotransfer into Skeletal Muscle for Protein Expression
Current Gene Therapy Nutraceuticals: Beyond the Diet Before the Drugs
Current Bioactive Compounds Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery Inhaled Nitric Oxide in Preterm Neonates with Refractory Hypoxemia Associated to Oligohydramnios
Current Drug Discovery Technologies Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency
Current Alzheimer Research Dermatologic Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews